|
1
|
Schindler C and Darnell JE Jr:
Transcriptional responses to polypeptide ligands: The JAK-STAT
pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quintás-Cardama A, Kantarjian H, Cortes J
and Verstovsek S: Janus kinase inhibitors for the treatment of
myeloproliferative neoplasias and beyond. Nat Rev Drug Discov.
10:127–140. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saharinen P, Takaluoma K and Silvennoinen
O: Regulation of the Jak2 tyrosine kinase by its pseudokinase
domain. Mol Cell Biol. 20:3387–3395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steensma DP, Dewald GW, Lasho TL, Powell
HL, McClure RF, Levine RL, Gilliland DG and Tefferi A: The JAK2
V617F activating tyrosine kinase mutation is an infrequent event in
both ‘atypical’ myeloproliferative disorders and myelodysplastic
syndromes. Blood. 106:1207–1209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lacronique V, Boureux A, Valle VD, Poirel
H, Quang CT, Mauchauffé M, Berthou C, Lessard M, Berger R, Ghysdael
J and Bernard OA: A TEL-JAK2 fusion protein with constitutive
kinase activity in human leukemia. Science. 278:1309–1312. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furqan M, Mukhi N, Lee B and Liu D:
Dysregulation of JAK-STAT pathway in hematological malignancies and
JAK inhibitors for clinical application. Biomark Res. 1:52013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta
S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, et al:
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor
AZD1480 potently suppresses growth of both primary and
castrate-resistant prostate cancer. Clin Cancer Res. 19:5658–5674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hedvat M, Huszar D, Herrmann A, Gozgit JM,
Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et
al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and
oncogenesis in solid tumors. Cancer cell. 16:487–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hart S, Goh KC, Novotny-Diermayr V, Hu CY,
Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, et al:
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the
treatment of myeloid and lymphoid malignancies. Leukemia.
25:1751–1759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scuto A, Krejci P, Popplewell L, Wu J,
Wang Y, Kujawski M, Kowolik C, Xin H, Chen L, Wang Y, et al: The
novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling,
resulting in suppression of human myeloma cell growth and survival.
Leukemia. 25:538–550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan S, Li Z and Thiele CJ: Inhibition of
STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor
growth in Neuroblastoma and Pediatric Sarcomas In vitro and In
vivo. Oncotarget. 4:433–445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Judd LM, Menheniott TR, Ling H, Jackson
CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of
the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and
in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee J, Han SY, Jung H, Yang J, Choi JW,
Chae CH, Park CH, Choi SU, Lee K, Ha JD, et al: Synthesis and
structure-activity relationship of aminopyridines with substituted
benzoxazoles as c-Met kinase inhibitors. Bioorg Med Chem Lett.
22:4044–4048. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chung HJ, Kamli MR, Lee HJ, Ha JD, Cho SY,
Lee J, Kong JY and Han SY: Discovery of quinolinone derivatives as
potent FLT3 inhibitors. Biochem Biophys Res Commun. 445:561–565.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho SY, Han SY, Ha JD, Ryu JW, Lee CO,
Jung H, Kang NS, Kim HR, Koh JS and Lee J: Discovery of
aminopyridines substituted with benzoxazole as orally active c-Met
kinase inhibitors. Bioorg Med Chem Lett. 20:4223–4227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanan EJ, van Abbema A, Barrett K, Blair
WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA,
et al: Discovery of potent and selective pyrazolopyrimidine janus
kinase 2 inhibitors. J Med Chem. 55:10090–11107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han MH, Park C, Kwon TK, Kim GY, Kim WJ,
Hong SH, Yoo YH and Choi YH: The histone deacetylase inhibitor
trichostatin a sensitizes human renal carcinoma cells to
TRAIL-induced apoptosis through down-regulation of c-FLIPL. Biomol
Ther (Seoul). 23:31–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vaddi K, Sarlis NJ and Gupta V:
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Expert Opin Pharmacother. 13:2397–2407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weinberg R: The Biology of Cancer. Second.
Taylor & Francis Group; 2013, View Article : Google Scholar
|
|
21
|
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY,
Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, et al: Evaluation of a
multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and
in vivo. Invest New Drugs. 30:518–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vyas D, O'Dell KM, Bandy JL and Boyce EG:
Tofacitinib: The first janus kinase (JAK) inhibitor for the
treatment of rheumatoid arthritis. Ann Pharmacother. 47:1524–1531.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dolgin E: Companies hope for kinase
inhibitor JAKpot. Nat Rev Drug Discov. 10:717–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ratner M: Setback for JAK2 inhibitors. Nat
Biotechnol. 32:1192014. View Article : Google Scholar : PubMed/NCBI
|
